C

Citius Oncology Inc
NASDAQ:CTOR

Watchlist Manager
Citius Oncology Inc
NASDAQ:CTOR
Watchlist
Price: 1.05 USD Market Closed
Market Cap: 87.7m USD

Net Margin

0%
Current
No historical data
Comparison unavailable

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
0%
=
$0
/
$0

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
0%
=
$0
/
$0

Peer Comparison

Country Company Market Cap Net
Margin
US
Citius Oncology Inc
NASDAQ:CTOR
87.7m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
377.1B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
177.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
156.2B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
111.7B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD
Loading...
AU
CSL Ltd
ASX:CSL
85.6B AUD
Loading...
NL
argenx SE
XBRU:ARGX
41.9B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
46.7B USD
Loading...
No Stocks Found

Market Distribution

Not Available
No Country distribution data available for this multiple

Citius Oncology Inc
Glance View

Market Cap
87.7m USD
Industry
Biotechnology

Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. The company is headquartered in New York City, New York. The company went IPO on 2022-10-14. The firm is focused on developing and commercializing targeted oncology therapies. The Company’s lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. The company is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the diphtheria toxin (DT) fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death.

CTOR Intrinsic Value
9.72 USD
Undervaluation 89%
Intrinsic Value
Price
C
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Back to Top